首页> 外文期刊>Cancer biology & therapy >Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma
【24h】

Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma

机译:总肿瘤基因组不稳定性:局部透明细胞肾细胞癌患者的无复发存活的重要预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

Measurement of a tumor's overall genomic instability has gathered recent interest over the identification of specific genomic imbalances, as it may provide a more robust measure of tumor aggressiveness. Here we demonstrate the association of tumor genomic instability in the prediction of disease recurrence in patients with clinically localized clear cell renal cell carcinoma (ccRCC). Genomic copy number analysis was performed using SNP-based microarrays on tumors from 103 ccRCC patients. The number of copy number alterations (CNAs) for each tumor was calculated, and a genomic imbalance threshold (GIT) associated with high stage and high-grade disease was determined. Cox proportional hazards regression analyzes were performed to assess the effect of GIT on recurrence-free survival adjusting for known confounders. In the cohort, copy number losses in chromosome arms 3p, 14q, 6q, 9p, and 1p and gains of 5q and 7p/q were common. CNA burden significantly increased with increasing stage (p = 9, defining the GIT. On regression analysis, GIT was a superior predictor of recurrence (Hazard Ratio 4.44 [CI 1.36-14.48], p = .01) independent of stage, with similar results adjusting for grade. These findings were confirmed using an alternative measure of genomic instability, weighted Genomic Integrity Index. Our data support a key role for genomic instability in ccRCC progression. More importantly, we have identified a GIT (>= 9 CNAs) that is a superior and independent predictor of disease recurrence in high-risk ccRCC patients.
机译:肿瘤的整体基因组不稳定性的测量已经聚集了最近对特定基因组失衡的鉴定感兴趣,因为它可能提供更强大的肿瘤侵袭性的衡量标准。在这里,我们证明了肿瘤基因组不稳定性在临床局部透明细胞肾细胞癌(CCRCC)患者患者疾病复发中的关联。基于SNP的微阵列对来自103例CCRCC患者的肿瘤进行基因组拷贝数分析。计算每种肿瘤的拷贝数改变(CNA)的数量,并确定与高级和高级别疾病相​​关的基因组不平衡阈值(Git)。 COX比例危害回归分析进行评估Git对无复发存活调整的疗效调整,以了解已知的混血。在队列中,染色体臂3p,14q,6q,9p和1p和5q和7p / q的增益中的拷贝数损失是常见的。 CNA负担随着阶段的增加而显着增加(P = 9,定义了Git。在回归分析中,Git是复发的优越预测因子(危险比4.44 [Ci 1.36-14.48],P = .01)独立于阶段,具有类似的结果调整等级。使用基因组不稳定性的替代测量来确认这些发现,加权基因组完整性指数。我们的数据支持CCRCC进展中基因组不稳定性的关键作用。更重要的是,我们已经确定了一个git(> = 9个CNA)高风险CCRCC患者中疾病复发的优越和独立预测因子。

著录项

  • 来源
    《Cancer biology & therapy》 |2020年第6期|共8页
  • 作者单位

    Fox Chase Canc Ctr Dept Surg Oncol Div Urol Oncol 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Biostat &

    Bioinformat 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Pathol Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Genom Facil 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Pathol Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Surg Oncol Div Urol Oncol 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Surg Oncol Div Urol Oncol 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Mol Therapeut Program 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Biostat &

    Bioinformat 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Biostat &

    Bioinformat 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Dept Surg Oncol Div Urol Oncol 7701 Burholme Ave Philadelphia PA 19111 USA;

    Fox Chase Canc Ctr Genom Facil 7701 Burholme Ave Philadelphia PA 19111 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    Kidney cancer; dna copy number analysis; genomic imbalances; recurrence-free survival;

    机译:肾癌;DNA拷贝数分析;基因组失衡;无复发存活;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号